可切除胰腺导管腺癌 upfront 术后无复发生存预测:基于 CA 19-9、CT 和 18F-FDG PET/CT 的术前风险评分
本研究回顾性开发并验证了整合 CA 19-9、CT 和 18F-FDG PET/CT 变量的术前风险评分,用于预测可切除胰腺导管腺癌 upfront 术后的无复发生存。风险评分包含肿瘤大小、肿瘤最大标准化摄取值≥5.2、可疑区域淋巴结、18F-FDG PET/CT 可能远处转移和 CA 19-9 五个变量。在测试集中,风险评分预测无复发生存的 C 指数为 0.61,与病理肿瘤分期的 0.64 相似(P=0.17)。
要点
- 风险评分基于术前 CA 19-9、CT 和 18F-FDG PET/CT 变量构建,用于预测可切除 PDAC upfront 术后无复发生存。
- 评分包含肿瘤大小、肿瘤最大标准化摄取值≥5.2、可疑区域淋巴结、18F-FDG PET/CT 可能远处转移和 CA 19-9。
- 测试集中风险评分 C 指数 0.61,与病理肿瘤分期 C 指数 0.64 相似(P=0.17)。
核心结论
- 基于术前 CA 19-9、CT 和 18F-FDG PET/CT 变量的风险评分可能有助于筛选可切除 PDAC 的高危患者。
研究设计与样本
- 回顾性研究,开发集为 2014 至 2017 年接受 upfront 手术的可切除 PDAC 患者,测试集为 2018 至 2019 年接受 upfront 手术的可切除 PDAC 患者,共 529 例,开发集 335 例(男 198 例,平均年龄 64±9 岁),测试集 194 例(男 103 例,平均年龄 66±9 岁)。
诊断标准与关键数值
- 风险评分包含五个变量:肿瘤大小(每增加 1 cm,HR 1.29,P<0.001)、肿瘤最大标准化摄取值≥5.2(HR 1.29,P=0.06)、可疑区域淋巴结(HR 1.43,P=0.02)、18F-FDG PET/CT 上可能远处转移(HR 2.32,P=0.03)、CA 19-9(每增加 100 U/mL,HR 1.02,P=0.002);测试集中风险评分预测无复发生存的 C 指数为 0.61,病理肿瘤分期 C 指数为 0.64(P=0.17)。
临床应用与阅片要点
- 作者认为该风险评分可能有助于筛选可切除 PDAC 的高危患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To develop and validate a preoperative risk score incorporating carbohydrate antigen (CA) 19-9, CT, and fluorine-18-fluorodeoxyglucose (18F-FDG) PET/CT variables to predict recurrence-free survival (RFS) after upfront surgery in patients with resectable pancreatic ductal adenocarcinoma (PDAC).
MATERIALS AND METHODS: Patients with resectable PDAC who underwent upfront surgery between 2014 and 2017 (development set) or between 2018 and 2019 (test set) were retrospectively evaluated. In the development set, a risk-scoring system was developed using the multivariable Cox proportional hazards model, including variables associated with RFS. In the test set, the performance of the risk score was evaluated using the Harrell C-index and compared with that of the postoperative pathological tumor stage.
RESULTS: A total of 529 patients, including 335 (198 male; mean age ± standard deviation, 64 ± 9 years) and 194 (103 male; mean age, 66 ± 9 years) patients in the development and test sets, respectively, were evaluated. The risk score included five variables predicting RFS: tumor size (hazard ratio [HR], 1.29 per 1 cm increment; P < 0.001), maximal standardized uptake values of tumor ≥ 5.2 (HR, 1.29; P = 0.06), suspicious regional lymph nodes (HR, 1.43; P = 0.02), possible distant metastasis on 18F-FDG PET/CT (HR, 2.32; P = 0.03), and CA 19-9 (HR, 1.02 per 100 U/mL increment; P = 0.002). In the test set, the risk score showed good performance in predicting RFS (C-index, 0.61), similar to that of the pathologic tumor stage (C-index, 0.64; P = 0.17).
CONCLUSION: The proposed risk score based on preoperative CA 19-9, CT, and 18F-FDG PET/CT variables may have clinical utility in selecting high-risk patients with resectable PDAC.
引用
- Jeong B, Oh M, Lee SS, et al. Predicting Recurrence-Free Survival After Upfront Surgery in Resectable Pancreatic Ductal Adenocarcinoma: A Preoperative Risk Score Based on CA 19-9, CT, and 18F-FDG PET/CT. Korean J Radiol. 2024. PMID: 38942458. doi:10.3348/kjr.2023.1235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。